E-Book, Englisch, 592 Seiten
Genomics, Proteomics, and the Nervous System
1. Auflage 2010
ISBN: 978-1-4419-7197-5
Verlag: Springer-Verlag
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)
E-Book, Englisch, 592 Seiten
ISBN: 978-1-4419-7197-5
Verlag: Springer-Verlag
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)
Autoren/Hrsg.
Weitere Infos & Material
1;Genomics, Proteomics,and the Nervous System;3
1.1;Preface;5
1.2;Contents;7
1.3;Contributors;11
1.4;Part I:Development;17
1.4.1;The Genomics of Turner Syndrome and Sex-Biased Neuropsychiatric Disorders;18
1.4.1.1;1 Turner Syndrome;18
1.4.1.1.1;1.1 Genetic Mechanisms Underlying TS Endophenotypes;20
1.4.1.1.2;1.2 Problems with Investigating the Genomics of TS;21
1.4.1.1.3;1.3 Identification of Candidate Genes for TS Endophenotypes;22
1.4.1.1.3.1;1.3.1 Human Studies;22
1.4.1.1.3.2;1.3.2 Mouse Studies;24
1.4.1.2;2 The Genomics of Sex-Biased Neuropsychiatric Disorders;26
1.4.1.3;3 Insights into Sex-Biased Neuropsychiatric Disorders from Turner Syndrome;28
1.4.1.4;4 Conclusion;29
1.4.1.5;References;30
1.4.2;Mental Retardation and Human Chromosome 21 Gene Overdosage: From Functional Genomics and Molecular Mechanisms Towards Prevention and Treatment of the Neuropathogenesis of Down Syndrome;36
1.4.2.1;1 Mental Retardation in Down Syndrome: An Invalidating Neuropathological Aspect with Hard Impact on Public Health;38
1.4.2.2;2 Mental Retardation in Down Syndrome: A Consequence of Developmental and Functional Brain Alterations;39
1.4.2.3;3 Mental Retardation in Down Syndrome: A Consequence of Chromosome 21 Gene Overdosage;41
1.4.2.3.1;3.1 Chromosomal Imbalance Effects on Mental Retardation;41
1.4.2.3.1.1;3.1.1 Dosage-Sensitive Gene Hypothesis;42
1.4.2.3.1.2;3.1.2 Amplified Developmental Instability Hypothesis;43
1.4.2.3.2;3.2 Gene Dosage Imbalance in Down Syndrome Determine Dysregulation of HSA21 Gene Expression;43
1.4.2.3.2.1;3.2.1 Primary and Secondary Gene Effects;43
1.4.2.3.2.2;3.2.2 Transcriptional Variation as a Consequence of Trisomy 21;44
1.4.2.3.2.3;3.2.3 Proteomic Variation as a Consequence of Trisomy 21;48
1.4.2.4;4 Modelling Neuronal Alterations and Mental Retardation in Mouse Models of Down Syndrome;51
1.4.2.4.1;4.1 Trisomic Mouse Models and Candidate Chromosomal Regions for Mental Retardation in Down Syndrome;52
1.4.2.4.1.1;4.1.1 Ts16 Mice: Trisomic for Most Part of HSA21 with Three Copies of Complete MMU16;53
1.4.2.4.1.2;4.1.2 Segmental Ts65Dn Mice: Trisomic for Most HSA21 Genes Conserved in Distal End of MMU16;53
1.4.2.4.1.3;4.1.3 Segmental Ts1Cje Mice: Trisomic for Three-Quarters of Genes of Ts65Dn, Including DSCR;55
1.4.2.4.1.4;4.1.4 Segmental Ms1Ts65 Mice: Trisomic for Non-DSCR Genes of Ts65Dn and Missing from Ts1Cje;55
1.4.2.4.1.5;4.1.5 Segmental Ts1Rhr and Ms1Rhr Mice: Trisomic and Monosomic for DSCR;56
1.4.2.4.1.6;4.1.6 Segmental Ts2Cje Mice: Trisomic from APP to the Telomere;56
1.4.2.4.1.7;4.1.7 Segmental Dp(16)1Yu Mice: Trisomic from LIP1 to ZNF295;57
1.4.2.4.1.8;4.1.8 Transchromosomal ES(#21) Mice: Trisomic for a Large Part of HSA21;57
1.4.2.4.1.9;4.1.9 Transchromosomal TC1 Mice: Trisomic for Almost HSA21 (92% of HSA21 Genes);58
1.4.2.4.1.10;4.1.10 Segmental Transgenic Mouse In Vivo Library of Human DSCR;58
1.4.2.5;5 Genetic Dissection of the Role of the Down Syndrome Critical Region in Mental Retardation;59
1.4.2.6;6 Transgenic Mouse Models of Down Syndrome;60
1.4.2.7;7 Candidate Genes and Genotype/Phenotype Correlation for Mental Retardation in Down Syndrome;61
1.4.2.7.1;7.1 Cu-Zn Superoxide Dismutase (SOD1) Gene;61
1.4.2.7.2;7.2 Amyloid Precursor Protein (APP) Gene;63
1.4.2.7.3;7.3 v-ets Erythroblastosis Virus E26 (ETS2) Gene;64
1.4.2.7.4;7.4 S100 Calcium Binding Protein B (S100B) Gene;64
1.4.2.7.5;7.5 Dual-Specificity Tyrosine Y Kinase 1 Subunit A (DYRK1A) Gene;65
1.4.2.7.6;7.6 Single-Minded (SIM2) Gene;66
1.4.2.7.7;7.7 Regulator of the Calcineurin (RCAN1) Gene;67
1.4.2.7.8;7.8 DOPEY2 Gene;68
1.4.2.7.9;7.9 Potassium Inwardly Rectifying Channel (KCNJ6) Gene;69
1.4.2.7.10;7.10 Tetratricopeptide Down Syndrome (TPRD) Gene;70
1.4.2.7.11;7.11 Down Syndrome Cell Adhesion Molecule (DSCAM) Gene;71
1.4.2.7.12;7.12 Synaptoganin 1 (SYNJ1) Gene;71
1.4.2.7.13;7.13 Intersectin 1 (ITSN1) Gene;72
1.4.2.7.14;7.14 Contribution of MicroRNAs in Down Syndrome Mental Retardation;73
1.4.2.8;8 Potential Molecular Pathways and Mechanisms Involved in Mental Retardation of Down Syndrome;74
1.4.2.8.1;8.1 Molecular and Cellular Mechanisms Leading to Mental Retardation in Down Syndrome;74
1.4.2.8.2;8.2 Molecular Pathways Contributing to Mental Retardation in Down Syndrome;76
1.4.2.9;9 Potential Directions for Mental Retardation Therapeutics in Down Syndrome;79
1.4.2.10;10 Conclusion and Perspectives;81
1.4.2.11;References;82
1.4.3;Epigenetic Programming of Stress Responses and Trans-Generational Inheritance Through Natural Variations in Maternal Care;102
1.4.3.1;1 Introduction: Environmental Influences and the Origins of Adult Health and Disease;103
1.4.3.2;2 Maternal Care in the Rat and HPA and Behavioral Responses to Stress in Adulthood;104
1.4.3.3;3 Epigenetic Gene Regulation: Heritable Changes in Gene Expression Potential;106
1.4.3.3.1;3.1 Chromatin Structure;106
1.4.3.3.2;3.2 DNA Methylation;107
1.4.3.3.3;3.3 DNA Demethylation;108
1.4.3.4;4 DNA Methylation and the Maternal Programming of Stress Responses;109
1.4.3.4.1;4.1 Epigenetic Programming by Maternal Care Is Reversible in the Adult Animal;110
1.4.3.4.2;4.2 Mechanisms Leading from Maternal Care to Chromatin Plasticity;112
1.4.3.5;5 Trans-Generational Inheritance of Epigenetic Programming by Maternal Behavior;113
1.4.3.5.1;5.1 Evidence for Epigenetic Mechanisms Linking Maternal Care of the Mother with Maternal Behavior in the Female Offspring;114
1.4.3.5.2;5.2 Environmental Influences and the Mother–Offspring Dyad;115
1.4.3.6;6 Epigenetic Programming Early in Life and Inter-Individual Differences in Human Behavior and Health;117
1.4.3.7;7 Concluding Remarks;118
1.4.3.8;References;119
1.4.4;Prenatal Viral Infection in Mouse: An Animal Model of Schizophrenia;128
1.4.4.1;1 An Introduction to Prenatal Viral Infectionand Schizophrenia;128
1.4.4.2;2 Mouse Brain Development;130
1.4.4.3;3 Impact of Prenatal Viral Infection on Brain Development;131
1.4.4.3.1;3.1 Brain Structural Abnormalities Following PrenatalViral Infection;131
1.4.4.3.2;3.2 Brain Gene Expression Abnormalities FollowingPrenatal Viral Infection;133
1.4.4.3.3;3.3 Altered Protein Expression in Offspring Following Prenatal Viral Infection;136
1.4.4.3.4;3.4 Brain Neurotransmitters are Altered in Exposed Offspring Following Viral Infection at E16 and E18;142
1.4.4.3.5;3.5 Abnormal Behavior of Offspring Following PrenatalViral Infection;143
1.4.4.4;4 Conclusions;143
1.4.4.5;References;146
1.4.5;Proteomic Actions of Growth Hormone in the Nervous System;152
1.4.5.1;1 Introduction;153
1.4.5.2;2 GH and Neural Action;154
1.4.5.3;3 GH and Neural Protein Synthesis;157
1.4.5.4;4 GH and Neural Growth and Differentiation;158
1.4.5.5;5 GH and Neuroprotection;161
1.4.5.6;6 GH and Neurotransmission;163
1.4.5.7;7 GH and Neuroendocrine Function;163
1.4.5.8;8 GH and Behavior;164
1.4.5.8.1;8.1 Summary;164
1.4.5.9;References;165
1.5;Part II:Learning and Memory;174
1.5.1;Gene Expression and Signal Transduction Cascades Mediating Estrogen Effectson Memory;175
1.5.1.1;1 Introduction;175
1.5.1.2;2 Synaptic Plasticity: A Memory Model;176
1.5.1.2.1;2.1 Long-Term Potentiation;177
1.5.1.3;3 Genomic Processes;178
1.5.1.3.1;3.1 Estrogen Receptors;178
1.5.1.3.1.1;3.1.1 Estrogen Receptor Localization;178
1.5.1.4;4 Rapid Signaling Cascades;179
1.5.1.4.1;4.1 Calcium Regulation;179
1.5.1.4.2;4.2 Alteration in Kinase and Phosphatase Activity;180
1.5.1.5;5 Interaction of Rapid Signaling Cascades and Transcription;180
1.5.1.5.1;5.1 Trophic and Neuroprotective Influences;182
1.5.1.5.2;5.2 Age-Related Changes in Estrogen Pathways;183
1.5.1.6;6 Conclusion;183
1.5.1.7;References;184
1.5.2;Diagnostic Genome Profiling in Mental Retardation;191
1.5.2.1;1 Introduction;191
1.5.2.2;2 Conventional Cytogenetics;193
1.5.2.3;3 Molecular Cytogenetics;193
1.5.2.3.1;3.1 Fluorescence In Situ Hybridization;193
1.5.2.3.2;3.2 Molecular Karyotyping;194
1.5.2.3.2.1;3.2.1 Clone-Based Genomic Microarrays;195
1.5.2.3.2.2;3.2.2 High-Density Oligonucleotide Microarrays;195
1.5.2.4;4 High Throughput Screening Technologies in Mental Retardation;197
1.5.2.4.1;4.1 Identification of Genes in Known Mental Retardation Syndromes;197
1.5.2.4.2;4.2 Targeted Microarray Applications;198
1.5.2.4.3;4.3 Genome-Wide Screening for DNA Copy-Number Variation;198
1.5.2.4.3.1;4.3.1 Identification of New Genomic Disorders;199
1.5.2.5;5 Copy-Number Variants in the General Population;200
1.5.2.6;6 The Clinical Consequences of Submicroscopic Copy-Number Variants;201
1.5.2.7;7 Conclusions and Future Prospects;203
1.5.2.8;References;203
1.5.3;Genomic Imprinting and Sexual Experience-Dependent Learning in the Mouse;209
1.5.3.1;1 Introduction;210
1.5.3.1.1;1.1 Olfaction and Male Reproduction;210
1.5.3.1.2;1.2 Genomic Imprinting and Reproduction;211
1.5.3.2;2 The Effects of Sexual Experience on Male Behaviour;212
1.5.3.2.1;2.1 Behavioural Responses to Sexual Experience;212
1.5.3.2.1.1;2.1.1 Sexual Experience and Reproductive Behaviours;212
1.5.3.2.1.2;2.1.2 Sexual Experience and Non-Reproductive Behaviours;213
1.5.3.2.2;2.2 Male Olfactory Learning and Sexual Experience;214
1.5.3.2.2.1;2.2.1 Sexual Experience and the Accessory Olfactory System;215
1.5.3.2.2.2;2.2.2 The Main Olfactory System and Male Reproductive Behaviour;216
1.5.3.2.2.3;2.2.3 Sexual Experience and the Main Olfactory System;217
1.5.3.2.3;2.3 Neuroendocrine Responses to Sexual Experience in the Male Brain;218
1.5.3.2.3.1;2.3.1 Sexual Experience and Androgens;218
1.5.3.2.3.2;2.3.2 Sexual Experience and Dopamine;219
1.5.3.2.3.3;2.3.3 Sexual Experience and Nitric Oxide;220
1.5.3.3;3 Genomic Imprinting;221
1.5.3.3.1;3.1 Imprinted Genes in the Brain;222
1.5.3.3.1.1;3.1.1 Imprinted Genes and Brain Development;222
1.5.3.3.1.2;3.1.2 Imprinted Genes and Brain Dysfunction;223
1.5.3.3.2;3.2 Evolution of Genomic Imprinting;224
1.5.3.3.2.1;3.2.1 Genomic Imprinting in Mammals;224
1.5.3.3.2.2;3.2.2 Hypotheses for the Evolution of Genomic Imprinting;225
1.5.3.3.2.3;3.2.3 Co-adaptation and Genomic Imprinting;225
1.5.3.4;4 Paternally Expressed Gene 3 (Peg3);226
1.5.3.4.1;4.1 Peg3, Maternal Behaviour and Offspring Development;226
1.5.3.4.1.1;4.1.1 Maternal Behaviour in Peg3 Mutant Mice;226
1.5.3.4.1.2;4.1.2 Reciprocal Effects in Peg3 Mutant Mothers and Offspring;227
1.5.3.4.2;4.2 Peg3 and Male Behaviour;227
1.5.3.4.2.1;4.2.1 Peg3 and Sexual Experience-Dependent Behavioural Changes;228
1.5.3.4.3;4.3 Peg3 and Forebrain Plasticity in Response to Sexual Experience;229
1.5.3.4.3.1;4.3.1 Peg3 and the Olfactory Systems;229
1.5.3.4.3.2;4.3.2 Peg3 and the Basal Forebrain;230
1.5.3.4.3.3;4.3.3 Peg3 and Hypothalamic Oxytocin;231
1.5.3.4.3.4;4.3.4 Peg3, Brain Development and Plasticiy;232
1.5.3.5;5 Conclusion;232
1.5.3.6;References;233
1.5.4;Proteomic Analysis of the Postsynaptic Density;240
1.5.4.1;1 Introduction;240
1.5.4.2;2 Composition of the PSD;242
1.5.4.2.1;2.1 Isolation of PSDs;242
1.5.4.2.2;2.2 Identification of Proteins in PSD Fractions;242
1.5.4.2.3;2.3 Problem of Contaminants;245
1.5.4.2.4;2.4 PSD Fractions of Higher Purity;246
1.5.4.2.4.1;2.4.1 N-Lauroyl-Sarcosinate-Derived PSD Fraction;247
1.5.4.2.4.2;2.4.2 Affinity Purification of PSD Fraction Using Magnetic Beads;247
1.5.4.2.5;2.5 Validation of PSD Constituents by Biochemical Techniques;249
1.5.4.2.6;2.6 Validation of PSD Constituents by Immuno-Electron Microscopy;251
1.5.4.2.7;2.7 Quantification;252
1.5.4.2.7.1;2.7.1 Absolute Quantification;252
1.5.4.2.7.2;2.7.2 Relative Quantification;253
1.5.4.3;3 Catching the Dynamics of the PSD;254
1.5.4.3.1;3.1 Studies Monitoring Changes in the PSD Composition;254
1.5.4.3.2;3.2 Problem of Postmortem Modifications When Using Whole Animals;255
1.5.4.3.3;3.3 Another Experimental Model: PSD fraction from Hippocampal Slices;255
1.5.4.4;4 Conclusions and Perspective;258
1.5.4.5;References;259
1.6;Part III:Behavior;263
1.6.1;Functional Genomic Dissection of Speechand Language Disorders;264
1.6.1.1;1 Human Speech and Language;265
1.6.1.2;2 Disorders of Speech and Language;265
1.6.1.2.1;2.1 Developmental Verbal Dyspraxia and the KE Family;266
1.6.1.2.2;2.2 Identifying a Gene Underlying Verbal Dyspraxia;267
1.6.1.3;3 FOX Transcription Factors;268
1.6.1.4;4 Functional Properties of FOXP2;270
1.6.1.4.1;4.1 Alternative Splicing of FOXP2;270
1.6.1.4.2;4.2 Functional Consequences of FOXP2 Mutations;273
1.6.1.4.3;4.3 R553H Affects Multiple Aspects of FOXP2 Function;274
1.6.1.4.4;4.4 R328X Yields an Unstable Non-Functional Product;275
1.6.1.5;5 Regulatory Networks Associated with Human Speech and Language;276
1.6.1.5.1;5.1 High Throughput Analysis of FOXP2 Target Genes;276
1.6.1.5.2;5.2 Unbiased Identification of FOXP2 Binding;279
1.6.1.5.3;5.3 CNTNAP2 is a Direct Target of FOXP2;281
1.6.1.5.4;5.4 FOXP2 and Common Forms of Language Disorder;283
1.6.1.6;6 Conclusions/Future Perspectives;284
1.6.1.7;References;284
1.6.2;Studying Human Circadian Behaviour Using Peripheral Cells;290
1.6.2.1;1 Introduction;290
1.6.2.1.1;1.1 Basic Mechanisms of the Circadian Clock;291
1.6.2.1.2;1.2 Central and Peripheral Oscillators;292
1.6.2.1.3;1.3 Communication Between the SCN and Periphery;294
1.6.2.1.4;1.4 Mutations in Clock Genes Affect Human Circadian Behaviour;295
1.6.2.1.5;1.5 Interaction Between the Circadian Clock and Mood Disorders;295
1.6.2.2;2 Measurement of Human Circadian Clocks;296
1.6.2.2.1;2.1 Reporter Assays in Peripheral Cells;297
1.6.2.2.2;2.2 Cell Type Considerations;297
1.6.2.3;3 Protocols;300
1.6.2.3.1;3.1 Overview of Requirements;300
1.6.2.3.1.1;3.1.1 Ethical Considerations;300
1.6.2.3.1.2;3.1.2 Use of Viruses;300
1.6.2.3.1.3;3.1.3 Storage of Samples;300
1.6.2.3.2;3.2 Producing the Reporter Virus;300
1.6.2.3.2.1;3.2.1 Calcium Phosphate Transfection in 293T Cells;301
1.6.2.3.2.2;3.2.2 Optimising Virus Production;302
1.6.2.3.3;3.3 Processing of Skin Biopsies;302
1.6.2.3.3.1;3.3.1 Preparation of the Skin;302
1.6.2.3.3.2;3.3.2 Punch;303
1.6.2.3.3.3;3.3.3 Biopsy Processing;303
1.6.2.3.3.4;3.3.4 Splitting Procedure;304
1.6.2.3.3.5;3.3.5 Freezing Procedure;304
1.6.2.3.3.6;3.3.6 Thawing Process;304
1.6.2.3.4;3.4 Measurement of Circadian Oscillations from Skin Biopsies;304
1.6.2.3.4.1;3.4.1 Fibroblast Infection;304
1.6.2.3.4.2;3.4.2 Measurement of Circadian Period Length;305
1.6.2.3.4.3;3.4.3 Phase Response Experiments;305
1.6.2.3.4.4;3.4.4 Phase Entrainment Experiments;305
1.6.2.3.4.5;3.4.5 Data Analyses;306
1.6.2.3.5;3.5 Troubleshooting;306
1.6.2.4;4 Discussion;307
1.6.2.4.1;4.1 Relationship Between the Circadian Oscillator and Other Pathologies;308
1.6.2.4.2;4.2 Ex Vivo Models;308
1.6.2.4.3;4.3 Future Potential;308
1.6.2.5;References;309
1.6.3;Genome-Wide Expression Profilesof Amygdala and Hippocampus in MiceAfter Fear Conditioning;314
1.6.3.1;1 Introduction;315
1.6.3.2;2 Fear Conditioning;316
1.6.3.2.1;2.1 Fear Conditioning and Amygdala;317
1.6.3.2.2;2.2 Fear Conditioning and Hippocampus;317
1.6.3.3;3 DNA Microarrays;318
1.6.3.4;4 Gene Expression Profiling in Amygdala and Hippocampus After Fear Conditioning;319
1.6.3.4.1;4.1 Methodologies;319
1.6.3.4.1.1;4.1.1 Animals and Fear Conditioning Training;319
1.6.3.4.1.2;4.1.2 Tissue Collection and RNA Extraction;320
1.6.3.4.1.3;4.1.3 Gene Expression Analysis;321
1.6.3.4.1.4;4.1.4 Real-Time RT-PCR and Immunohistochemistry;321
1.6.3.4.2;4.2 Distinct Gene Expression Patterns Induced by Fear Conditioning in Amygdala and Hippocampus;322
1.6.3.4.2.1;4.2.1 Fear Conditioning-Triggered Gene Expression Profiles in the Amygdala;332
1.6.3.4.2.2;4.2.2 Fear Conditioning-Triggered Gene Expression Profilesin the Hippocampus;334
1.6.3.5;5 Summary;335
1.6.3.6;References;336
1.7;Part IV:Psychiatric Disorders;341
1.7.1;Genetic Studies of Schizophrenia;342
1.7.1.1;1 Introduction;342
1.7.1.2;2 Genetic Epidemiology: Why Are We Looking for Genes Contributing to Schizophrenia?;344
1.7.1.2.1;2.1 Family Studies: Does Risk Aggregate in Relatives?;345
1.7.1.2.2;2.2 Twin Studies: How Large Is the Genetic Component of Risk?;346
1.7.1.2.3;2.3 Adoption Studies: Is Familial Aggregation Due to Shared Environment?;347
1.7.1.2.4;2.4 Transmission Models: How Is the Genetic Risk Transmitted?;348
1.7.1.2.5;2.5 Spectrum Disorders: How Broad Is the Range of Psychiatric Illness Transmitted and Who Do We Consider Affected?;350
1.7.1.3;3 Methods: Where and How Will Such Genes Be Found?;352
1.7.1.3.1;3.1 Approaches: What Are Linkage and Association?;352
1.7.1.3.2;3.2 Linkage;352
1.7.1.3.3;3.3 Linkage Analysis Methods;354
1.7.1.3.4;3.4 Association;355
1.7.1.3.5;3.5 Association Analysis Methods;355
1.7.1.3.6;3.6 Limitations of Linkage and Association;356
1.7.1.3.7;3.7 DNA Polymorphisms;357
1.7.1.4;4 Results: Where Is the Evidence Strongest for Schizophrenia Susceptibility Genes?;358
1.7.1.4.1;4.1 Chromosome 22q Linkage Studies;358
1.7.1.4.2;4.2 Chromosome 22q Candidate Genes;359
1.7.1.4.2.1;4.2.1 COMT;359
1.7.1.4.3;4.3 Chromosome 8p22-p21 Linkage Studies;360
1.7.1.4.4;4.4 Chromosome 8p22-p21 Candidate Genes;360
1.7.1.4.4.1;4.4.1 NRG1;360
1.7.1.4.4.2;4.4.2 NRG1 and ERBB4;361
1.7.1.4.5;4.5 Chromosome 6p24-p22 Linkage Studies;361
1.7.1.4.6;4.6 Chromosome 6p24-p22 Candidate Genes;361
1.7.1.4.6.1;4.6.1 DTNBP1;361
1.7.1.4.6.2;4.6.2 Chromosome 13q14-q32 Linkage Studies;365
1.7.1.4.7;4.7 Chromosome 13q14-q32 Candidate Genes;365
1.7.1.4.7.1;4.7.1 G72/DAOA;365
1.7.1.4.7.2;4.7.2 G72/DAOA and DAO;366
1.7.1.4.8;4.8 Chromosome 1q32-q42 Linkage Studies;366
1.7.1.4.8.1;4.8.1 1q41-q42 and DISC1;366
1.7.1.4.9;4.9 1q23-q32 linkage and RGS4;367
1.7.1.4.10;4.10 Other Chromosomal Regions and Genes;368
1.7.1.4.11;4.11 Meta-Analyses of Linkage and Association Data;368
1.7.1.4.12;4.12 Summary of Current Gene Findings;369
1.7.1.4.13;4.13 Genomewide Association Studies;370
1.7.1.4.14;4.14 Rare Structural Variation in Schizophrenia;371
1.7.1.5;5 Discussion;373
1.7.1.6;6 Conclusions;374
1.7.1.7;References;375
1.7.2;Proteomics of the Anterior Cingulate Cortex in Schizophrenia;390
1.7.2.1;1 Introduction;391
1.7.2.2;2 Cross-Correlation of Altered Proteins in Different Brain Region, Disease and Risperidone-Treated Rats;392
1.7.2.2.1;2.1 Human ACC Samples of Schizophrenia Subjects and 2DE-Based Proteomic Analysis;392
1.7.2.2.2;2.2 Changes in the ACC GM and WM Proteomes in Schizophrenia Relative to Healthy Controls;393
1.7.2.2.3;2.3 Cross-Correlation of Identified Proteins in the ACC WM and GM Proteome in Schizophrenia;394
1.7.2.2.4;2.4 Cross-Correlation of Altered Proteins in the ACC in Schizophrenia and Prefrontal Cortex Brodmann Area 9 (PFC BA9) inAlcoholism ;396
1.7.2.2.5;2.5 Altered Proteins of the Schizophrenia ACC vs. Altered Proteins Due to Neuroleptics in Animal Brain;397
1.7.2.3;3 Schizophrenia ACC-Specific Protein Changes;398
1.7.2.4;4 Conclusions;405
1.7.2.5;References;405
1.7.3;Proteome Effects of Antidepressant Medications;408
1.7.3.1;1 Introduction;409
1.7.3.2;2 Antidepressant Treatments;410
1.7.3.2.1;2.1 Pharmacotherapy;410
1.7.3.2.2;2.2 Other Antidepressant Treatments;410
1.7.3.3;3 Proteomic Approaches for Aiding the Discovery of Novel Antidepressants;412
1.7.3.4;4 Proteomic Analyses After Antidepressant Treatments;413
1.7.3.4.1;4.1 Antidepressive Agents;413
1.7.3.4.1.1;4.1.1 Proteomics in the Early Days;413
1.7.3.4.1.2;4.1.2 Proteomics in the New Millennium;430
1.7.3.4.1.3;4.1.3 Proteomic Investigations in Cellular Models;435
1.7.3.4.2;4.2 Non-Pharmacologic Interventions;435
1.7.3.5;5 Critical Evaluations of Proteomic Techniques in Studies with Antidepressants;436
1.7.3.5.1;5.1 2D Gel Electrophoresis;436
1.7.3.5.2;5.2 Gel Matching and Differential Analysis;437
1.7.3.5.3;5.3 Protein Identification;438
1.7.3.5.4;5.4 Result Confirmation;439
1.7.3.6;6 Ongoing Studies;439
1.7.3.7;7 An Integrative Overview of Proteomic Findings;441
1.7.3.8;References;446
1.8;Part V:Neurological Disorders;451
1.8.1;MicroRNAs in Neurodegenerative Disorders;452
1.8.1.1;1 Introduction;452
1.8.1.2;2 MicroRNAs (miRNAs): A Widespread Class of Small RNA Molecules that Regulate Protein Expression;453
1.8.1.2.1;2.1 Overview of the Mammalian miRNA Expression Pathway (see Fig. 1 and review in Winter, Jung, Keller, Gregory, & Diederichs (2009);453
1.8.1.2.2;2.2 Mechanisms of miRNA Posttranscriptional Regulation;454
1.8.1.3;3 Regulatory Roles of miRNAs in Synapse Formation;455
1.8.1.4;4 A Role for miRNA Dysregulation in Neurodegenerative Disorders;456
1.8.1.4.1;4.1 Neurodegeneration as a Consequence of Deficits in miRNA Processing;456
1.8.1.4.2;4.2 miRNA Dysregulation in Human Neurodegenerative Disorders;457
1.8.1.4.3;4.3 Loss of miRNA Target Gene Binding Is Associated with Neurodegeneration;458
1.8.1.5;5 Conclusions and Future Perspectives;458
1.8.1.6;References;459
1.8.2;Specific and Surrogate Cerebrospinal Fluid Markers in Creutzfeldt–Jakob Disease;462
1.8.2.1;1 Introduction;463
1.8.2.2;2 Search for Pathological Values in Cerebrospinal Fluid of sCJD Patients;463
1.8.2.2.1;2.1 The Search for PrPSc;464
1.8.2.2.2;2.2 Search for Surrogate Markers;465
1.8.2.2.3;2.3 2D-PAGE Approach;466
1.8.2.3;3 Future Perspectives;468
1.8.2.4;References;470
1.8.3;Genome-Wide Expression Studies in Autism-Spectrum Disorders: Moving from Neurodevelopment to Neuroimmunology;475
1.8.3.1;1 Introduction;476
1.8.3.2;2 Genome-Wide Expression Studies in Autism Spectrum Disorders;477
1.8.3.3;3 Abnormal Immunity and Neuroinflammation in Autism;485
1.8.3.4;4 Conclusions and Future Perspectives;488
1.8.3.5;References;489
1.8.4;Protein Expression Profile of Alzheimer’s Disease Mouse Model Generated by Difference Gel Electrophoresis (DIGE) Approach;494
1.8.4.1;1 Introduction;495
1.8.4.2;2 Transgenic Mouse Model as a Tool for Studyof Alzheimer’s Disease Proteome;496
1.8.4.3;3 Generation of AD Proteomic Profile by DIGE Analysis;497
1.8.4.3.1;3.1 Sample Preparation and Labeling;498
1.8.4.3.2;3.2 Protein Separation and Determination of Differentiating Spots;498
1.8.4.3.3;3.3 MS Identification of Regulated Proteins;501
1.8.4.3.4;3.4 Analysis of Resulting Protein Set;503
1.8.4.4;4 Resulting Protein Expression Profile in Relation to the Current Knowledge of Alzheimer Disease;506
1.8.4.5;5 Conclusion and Perspectives;510
1.8.4.6;References;511
1.8.5;Proteomic Analysis of CNS Injury and Recovery;516
1.8.5.1;1 Introduction;517
1.8.5.2;2 Proteomics of Injury-Associated Proteins in the Mammalian CNS;517
1.8.5.2.1;2.1 Traumatic Brain Injury;517
1.8.5.2.1.1;2.1.1 Traumatic Brain Injury During Early Postnatal Development;517
1.8.5.2.1.2;2.1.2 Traumatic Brain Injury During Adulthood;519
1.8.5.2.2;2.2 Spinal Cord Injury;521
1.8.5.3;3 Proteome Analysis of Injury-Related Plasticity of the Mammalian Brain;522
1.8.5.3.1;3.1 Vestibular Compensation: The Restoration of Vestibular Function After Injury;522
1.8.5.3.2;3.2 Differential Proteome Analysis of Proteins Involved in Vestibular Compensation;523
1.8.5.4;4 Biomarkers of CNS Injury;524
1.8.5.4.1;4.1 Criteria for Useful Biomarkers;524
1.8.5.4.2;4.2 Production, Composition, and Function of the Cerebrospinal Fluid;524
1.8.5.4.3;4.3 Toward a Molecular Identification of Biomarkers of CNS Injury in Humans;525
1.8.5.5;5 Comparative Proteomic Analysis of Regeneration-Competent vs. Regeneration-Deficient Systems;526
1.8.5.5.1;5.1 Comparative Proteomics as a Strategy to Identify Novel Signals Associated with Regeneration;526
1.8.5.5.2;5.2 Regenerative Potential in the Teleost Fish Brain;527
1.8.5.5.3;5.3 Proteome Analysis of Proteins Involved in Repair of the Teleostean Brain;528
1.8.5.6;6 Potential Problems and Limitations of Proteome Analysis of Brain Injury-Associated Proteins;533
1.8.5.7;7 Perspectives;535
1.8.5.8;References;536
1.8.6;MALDI Imaging of Formalin-Fixed Paraffin-Embedded Tissues: Application to Model Animals of Parkinson Diseasefor Biomarker Hunting;542
1.8.6.1;1 What is MALDI Imaging Mass Spectrometry Procedure?;542
1.8.6.2;2 Application of MALDI-MSI to Brain Analyses;545
1.8.6.3;3 How to Apply MALDI-MSI to Archived Tissue in FFPE;546
1.8.6.4;4 Application of MALDI-MSI to Neurodegenerative Diseases: Parkinson’s Disease;547
1.8.6.5;References;556
1.8.7;Comparative Proteomic Analysis as a Method to Investigate Inflammatory and Neuropathic Pain;562
1.8.7.1;1 Introduction;563
1.8.7.2;2 Nociceptive Pain;563
1.8.7.2.1;2.1 Animal Models of Nociceptive Pain;564
1.8.7.2.1.1;2.1.1 Zymosan-Induced Paw Inflammation;564
1.8.7.3;3 Neuropathic Pain;564
1.8.7.3.1;3.1 Animal Models of Neuropathic Pain;565
1.8.7.3.1.1;3.1.1 Central Models;565
1.8.7.3.1.1.1;Weight Drop Model;565
1.8.7.3.1.1.2;Spinal Cord Hemisection;566
1.8.7.3.1.2;3.1.2 Peripheral Models;566
1.8.7.3.1.2.1;Spinal Nerve Ligation;567
1.8.7.3.1.2.2;Partial Nerve Ligation;567
1.8.7.3.1.2.3;Chronic Constriction Injury of the Sciatic Nerve;567
1.8.7.4;4 Proteomics;567
1.8.7.4.1;4.1 2D PAGE;568
1.8.7.4.2;4.2 Identification of 2D-Separated Proteins;569
1.8.7.5;5 Protein Expression Following Peripheral Inflammation;569
1.8.7.6;6 Protein Expression Following Neuropathic Pain;570
1.8.7.7;7 Conclusion;572
1.8.7.8;References;583
1.9;Index;588




